Skip to main content
Top
Published in: BMC Cancer 1/2006

Open Access 01-12-2006 | Research article

Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression

Authors: Teri L Larkins, Marchele Nowell, Shailesh Singh, Gary L Sanford

Published in: BMC Cancer | Issue 1/2006

Login to get access

Abstract

Background

Cyclooxygenase (COX) is the rate-limiting enzyme that catalyzes the formation of prostaglandins. The inducible isoform of COX (COX-2) is highly expressed in aggressive metastatic breast cancers and may play a critical role in cancer progression (i.e. growth and metastasis). However, the exact mechanism(s) for COX-2-enhanced metastasis has yet to be clearly defined. It is well established that one of the direct results of COX-2 action is increased prostaglandin production, especially prostaglandin E2 (PGE2). Here, we correlate the inhibition of COX-2 activity with decreased breast cancer cell proliferation, migration, invasion and matrix metalloproteinase (MMP) expression.

Methods

Breast cancer cells (Hs578T, MDA-MB-231 and MCF-7) were treated with selective COX-2 inhibitors (NS-398 and Niflumic acid, NA). Cell proliferation was measured by staining with erythrosin B and counting the viable cells using a hemacytometer. Cell migration and invasion were measured using migration and invasion chamber systems. MMP expression was determined by enzyme immunoassay (secreted protein) and real-time quantitative polymerase chain reaction (mRNA).

Results

Our results show that there is a decline in proliferation, migration and invasion by the Hs578T and MDA-MB-231 breast cancer cell lines in the presence of either low concentrations (1 μM or lower) NA or NS-398. We also report that MMP mRNA and protein expression by Hs578T cells is inhibited by NS-398; there was a 50% decrease by 100 μM NS-398. PGE2 completely reversed the inhibitory effect of NS-398 on MMP mRNA expression.

Conclusion

Our data suggests that COX-2-dependent activity is a necessary component for cellular and molecular mechanisms of breast cancer cell motility and invasion. COX-2 activity also modulates the expression of MMPs, which may be a part of the molecular mechanism by which COX-2 promotes cell invasion and migration. The studies suggest that COX-2 assists in determining and defining the metastatic signaling pathways that promote the breast cancer progression to metastasis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM: Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol. 1997, 10: 503-507.PubMed Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM: Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol. 1997, 10: 503-507.PubMed
2.
go back to reference Gilhooly EM, Rose DP: The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol. 1999, 15: 267-270.PubMed Gilhooly EM, Rose DP: The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol. 1999, 15: 267-270.PubMed
3.
go back to reference Liu XH, Rose DP: Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996, 56: 5125-5127.PubMed Liu XH, Rose DP: Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996, 56: 5125-5127.PubMed
4.
go back to reference Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62: 632-635.PubMed Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002, 62: 632-635.PubMed
5.
go back to reference Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001, 276: 18563-18569. 10.1074/jbc.M010787200.CrossRefPubMed Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001, 276: 18563-18569. 10.1074/jbc.M010787200.CrossRefPubMed
6.
go back to reference Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A: COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol. 2005, 26: 1393-1399.PubMed Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A: COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol. 2005, 26: 1393-1399.PubMed
7.
go back to reference Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst. 1980, 64: 1061-1070.PubMed Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M: Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst. 1980, 64: 1061-1070.PubMed
8.
go back to reference Karmali RA, Welt S, Thaler HT, Lefevre F: Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer. 1983, 48: 689-696.CrossRefPubMedPubMedCentral Karmali RA, Welt S, Thaler HT, Lefevre F: Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer. 1983, 48: 689-696.CrossRefPubMedPubMedCentral
9.
go back to reference Zhao Y, Agarwal VR, Mendelson CR, Simpson ER: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 1996, 137: 5739-5742. 10.1210/en.137.12.5739.PubMed Zhao Y, Agarwal VR, Mendelson CR, Simpson ER: Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 1996, 137: 5739-5742. 10.1210/en.137.12.5739.PubMed
10.
go back to reference Dormond O, Foletti A, Paroz C, Ruegg C: NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med. 2001, 7: 1041-1047. 10.1038/nm0901-1041.CrossRefPubMed Dormond O, Foletti A, Paroz C, Ruegg C: NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med. 2001, 7: 1041-1047. 10.1038/nm0901-1041.CrossRefPubMed
11.
go back to reference Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000, 19: 19-27. 10.1023/A:1026575610124.CrossRefPubMed Gately S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000, 19: 19-27. 10.1023/A:1026575610124.CrossRefPubMed
12.
go back to reference Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, Inoue H, Tanabe T, Yoshimoto T: Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett. 1999, 460: 145-148. 10.1016/S0014-5793(99)01328-9.CrossRefPubMed Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, Inoue H, Tanabe T, Yoshimoto T: Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett. 1999, 460: 145-148. 10.1016/S0014-5793(99)01328-9.CrossRefPubMed
13.
go back to reference Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, Turpeenniemi-Hujanen T: Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat. 2005, 89: 215-220. 10.1007/s10549-004-0714-4.CrossRefPubMed Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimaki A, Turpeenniemi-Hujanen T: Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat. 2005, 89: 215-220. 10.1007/s10549-004-0714-4.CrossRefPubMed
14.
go back to reference Guyton DP, Evans DM, Sloan-Stakleff KD: Urokinase Plasminogen Activator Receptor (uPAR): A Potential Indicator of Invasion for In Situ Breast Cancer. Breast J. 2000, 6: 130-136. 10.1046/j.1524-4741.2000.99025.x.CrossRefPubMed Guyton DP, Evans DM, Sloan-Stakleff KD: Urokinase Plasminogen Activator Receptor (uPAR): A Potential Indicator of Invasion for In Situ Breast Cancer. Breast J. 2000, 6: 130-136. 10.1046/j.1524-4741.2000.99025.x.CrossRefPubMed
15.
go back to reference Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000, 60: 4629-4637.PubMed Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000, 60: 4629-4637.PubMed
16.
go back to reference Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997, 94: 3336-3340. 10.1073/pnas.94.7.3336.CrossRefPubMedPubMedCentral Tsujii M, Kawano S, DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997, 94: 3336-3340. 10.1073/pnas.94.7.3336.CrossRefPubMedPubMedCentral
17.
go back to reference Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S, Dubinett SM: Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem. 2002, 277: 50828-50833. 10.1074/jbc.M210707200.CrossRefPubMedPubMedCentral Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S, Dubinett SM: Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem. 2002, 277: 50828-50833. 10.1074/jbc.M210707200.CrossRefPubMedPubMedCentral
18.
go back to reference Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994, 5: 138-146.CrossRefPubMed Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994, 5: 138-146.CrossRefPubMed
19.
go back to reference Harris RE, Namboodiri KK, Farrar WB: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996, 7: 203-205.CrossRefPubMed Harris RE, Namboodiri KK, Farrar WB: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology. 1996, 7: 203-205.CrossRefPubMed
20.
go back to reference Kawamori T, Rao CV, Seibert K, Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998, 58: 409-412.PubMed Kawamori T, Rao CV, Seibert K, Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998, 58: 409-412.PubMed
21.
go back to reference Kundu N, Fulton AM: Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res. 2002, 62: 2343-2346.PubMed Kundu N, Fulton AM: Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res. 2002, 62: 2343-2346.PubMed
22.
go back to reference Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ: Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med. 1997, 216: 201-210.CrossRefPubMed Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ: Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med. 1997, 216: 201-210.CrossRefPubMed
23.
go back to reference Norrish AE, Jackson RT, McRae CU: Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer. 1998, 77: 511-515. 10.1002/(SICI)1097-0215(19980812)77:4<511::AID-IJC6>3.0.CO;2-X.CrossRefPubMed Norrish AE, Jackson RT, McRae CU: Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer. 1998, 77: 511-515. 10.1002/(SICI)1097-0215(19980812)77:4<511::AID-IJC6>3.0.CO;2-X.CrossRefPubMed
24.
go back to reference Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002, 62: 1676-1681.PubMed Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002, 62: 1676-1681.PubMed
25.
go back to reference Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JWJ: Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res. 2004, 10: 8743-8750. 10.1158/1078-0432.CCR-04-0266.CrossRefPubMed Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JWJ: Expression and functional role of CCR9 in prostate cancer cell migration and invasion. Clin Cancer Res. 2004, 10: 8743-8750. 10.1158/1078-0432.CCR-04-0266.CrossRefPubMed
26.
go back to reference Mundy GR, Yoneda T: Facilitation and suppression of bone metastasis. Clin Orthop Relat Res. 1995, 34-44. Mundy GR, Yoneda T: Facilitation and suppression of bone metastasis. Clin Orthop Relat Res. 1995, 34-44.
27.
go back to reference Harris RE, Alshafie GA, bou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000, 60: 2101-2103.PubMed Harris RE, Alshafie GA, bou-Issa H, Seibert K: Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 2000, 60: 2101-2103.PubMed
28.
go back to reference Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P: Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 2005, 7: R422-R435. 10.1186/bcr1019.CrossRefPubMedPubMedCentral Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P: Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 2005, 7: R422-R435. 10.1186/bcr1019.CrossRefPubMedPubMedCentral
29.
go back to reference Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, Sabichi AL: Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep. 2006, 15: 471-477.PubMed Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, Sabichi AL: Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep. 2006, 15: 471-477.PubMed
30.
go back to reference Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T: Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006, 66: 2067-2073. 10.1158/0008-5472.CAN-05-2012.CrossRefPubMed Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T: Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006, 66: 2067-2073. 10.1158/0008-5472.CAN-05-2012.CrossRefPubMed
31.
go back to reference Liu XH, Yao S, Kirschenbaum A, Levine AC: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 1998, 58: 4245-4249.PubMed Liu XH, Yao S, Kirschenbaum A, Levine AC: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 1998, 58: 4245-4249.PubMed
32.
go back to reference Mohseni H, Zaslau S, McFadden D, Riggs DR, Jackson BJ, Kandzari S: COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. J Surg Res. 2004, 119: 138-142. 10.1016/j.jss.2004.03.005.CrossRefPubMed Mohseni H, Zaslau S, McFadden D, Riggs DR, Jackson BJ, Kandzari S: COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. J Surg Res. 2004, 119: 138-142. 10.1016/j.jss.2004.03.005.CrossRefPubMed
33.
go back to reference Chan CM, Ma BB, Wong SC, Chan AT: Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression. Biomed Pharmacother. 2005, 59 Suppl 2: S268-S271. 10.1016/S0753-3322(05)80043-5.CrossRefPubMed Chan CM, Ma BB, Wong SC, Chan AT: Celecoxib induces dose dependent growth inhibition in nasopharyngeal carcinoma cell lines independent of cyclooxygenase-2 expression. Biomed Pharmacother. 2005, 59 Suppl 2: S268-S271. 10.1016/S0753-3322(05)80043-5.CrossRefPubMed
34.
go back to reference Elder DJ, Halton DE, Hague A, Paraskeva C: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res. 1997, 3: 1679-1683.PubMed Elder DJ, Halton DE, Hague A, Paraskeva C: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res. 1997, 3: 1679-1683.PubMed
35.
go back to reference Han S, Roman J: COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals. Lung Cancer. 2006, 51: 283-296. 10.1016/j.lungcan.2005.10.015.CrossRefPubMed Han S, Roman J: COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals. Lung Cancer. 2006, 51: 283-296. 10.1016/j.lungcan.2005.10.015.CrossRefPubMed
36.
go back to reference Gao XQ, Han JX, Huang HY, Song B, Zhu B, Song CZ: Effect of NS398 on metastasis-associated gene expression in a human colon cancer cell line. World J Gastroenterol. 2005, 11: 4337-4343.CrossRefPubMedPubMedCentral Gao XQ, Han JX, Huang HY, Song B, Zhu B, Song CZ: Effect of NS398 on metastasis-associated gene expression in a human colon cancer cell line. World J Gastroenterol. 2005, 11: 4337-4343.CrossRefPubMedPubMedCentral
37.
go back to reference Rozic JG, Chakraborty C, Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer. 2001, 93: 497-506. 10.1002/ijc.1376.CrossRefPubMed Rozic JG, Chakraborty C, Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer. 2001, 93: 497-506. 10.1002/ijc.1376.CrossRefPubMed
38.
go back to reference Yao M, Lam EC, Kelly CR, Zhou W, Wolfe MM: Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer. 2004, 90: 712-719. 10.1038/sj.bjc.6601489.CrossRefPubMedPubMedCentral Yao M, Lam EC, Kelly CR, Zhou W, Wolfe MM: Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br J Cancer. 2004, 90: 712-719. 10.1038/sj.bjc.6601489.CrossRefPubMedPubMedCentral
39.
go back to reference Matsumoto G, Rahman MA, Muta M, Nakamura T, Bando H, Saji S, Tsuruta K, Okamoto A, Toi M: DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice. Oncol Rep. 2004, 12: 281-285.PubMed Matsumoto G, Rahman MA, Muta M, Nakamura T, Bando H, Saji S, Tsuruta K, Okamoto A, Toi M: DFU, a selective COX-2 inhibitor, suppresses MCF-7 xenograft tumor growth in mice. Oncol Rep. 2004, 12: 281-285.PubMed
40.
go back to reference Srinath P, Rao PN, Knaus EE, Suresh MR: Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res. 2003, 23: 3923-3928.PubMed Srinath P, Rao PN, Knaus EE, Suresh MR: Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res. 2003, 23: 3923-3928.PubMed
41.
go back to reference Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 1997, 99: 2254-2259.CrossRefPubMedPubMedCentral Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 1997, 99: 2254-2259.CrossRefPubMedPubMedCentral
42.
go back to reference Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E, Evans JF, Wolfe MM: Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res. 2003, 63: 586-592.PubMed Yao M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, Kwong E, Evans JF, Wolfe MM: Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res. 2003, 63: 586-592.PubMed
43.
go back to reference Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 2000, 164: 820-825. 10.1016/S0022-5347(05)67321-1.CrossRefPubMed Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC: Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 2000, 164: 820-825. 10.1016/S0022-5347(05)67321-1.CrossRefPubMed
44.
go back to reference Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997, 89: 1260-1270. 10.1093/jnci/89.17.1260.CrossRefPubMed Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997, 89: 1260-1270. 10.1093/jnci/89.17.1260.CrossRefPubMed
45.
go back to reference Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000, 2: 252-257. 10.1186/bcr65.CrossRefPubMedPubMedCentral Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000, 2: 252-257. 10.1186/bcr65.CrossRefPubMedPubMedCentral
46.
go back to reference Barsky SH, Togo S, Garbisa S, Liotta LA: Type IV collagenase immunoreactivity in invasive breast carcinoma. Lancet. 1983, 1: 296-297. 10.1016/S0140-6736(83)91708-7.CrossRefPubMed Barsky SH, Togo S, Garbisa S, Liotta LA: Type IV collagenase immunoreactivity in invasive breast carcinoma. Lancet. 1983, 1: 296-297. 10.1016/S0140-6736(83)91708-7.CrossRefPubMed
47.
go back to reference Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM: Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis. 1998, 16: 577-585. 10.1023/A:1006580415796.CrossRefPubMed Pacheco MM, Mourao M, Mantovani EB, Nishimoto IN, Brentani MM: Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis. 1998, 16: 577-585. 10.1023/A:1006580415796.CrossRefPubMed
48.
go back to reference Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y: Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res. 1996, 87: 602-611.CrossRefPubMed Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y: Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res. 1996, 87: 602-611.CrossRefPubMed
49.
go back to reference Futaki N, Takahashi S, Kitagawa T, Yamakawa Y, Tanaka M, Higuchi S: Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo. Inflamm Res. 1997, 46: 496-502. 10.1007/s000110050232.CrossRefPubMed Futaki N, Takahashi S, Kitagawa T, Yamakawa Y, Tanaka M, Higuchi S: Selective inhibition of cyclooxygenase-2 by NS-398 in endotoxin shock rats in vivo. Inflamm Res. 1997, 46: 496-502. 10.1007/s000110050232.CrossRefPubMed
50.
go back to reference Ogino K, Hatanaka K, Kawamura M, Katori M, Harada Y: Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology. 1997, 55: 44-53.CrossRefPubMed Ogino K, Hatanaka K, Kawamura M, Katori M, Harada Y: Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology. 1997, 55: 44-53.CrossRefPubMed
51.
go back to reference Rigas B, Goldman IS, Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993, 122: 518-523.PubMed Rigas B, Goldman IS, Levine L: Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993, 122: 518-523.PubMed
52.
go back to reference Uefuji K, Ichikura T, Mochizuki H: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res. 2000, 6: 135-138.PubMed Uefuji K, Ichikura T, Mochizuki H: Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res. 2000, 6: 135-138.PubMed
53.
go back to reference Wang D, DuBois RN: Prostaglandins and cancer. Gut. 2005 Wang D, DuBois RN: Prostaglandins and cancer. Gut. 2005
54.
go back to reference Tjandrawinata RR, Hughes-Fulford M: Up-regulation of cyclooxygenase-2 by product-prostaglandin E2. Adv Exp Med Biol. 1997, 407: 163-170.CrossRefPubMed Tjandrawinata RR, Hughes-Fulford M: Up-regulation of cyclooxygenase-2 by product-prostaglandin E2. Adv Exp Med Biol. 1997, 407: 163-170.CrossRefPubMed
55.
go back to reference Tjandrawinata RR, Dahiya R, Hughes-Fulford M: Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer. 1997, 75: 1111-1118.CrossRefPubMedPubMedCentral Tjandrawinata RR, Dahiya R, Hughes-Fulford M: Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer. 1997, 75: 1111-1118.CrossRefPubMedPubMedCentral
56.
go back to reference Pan MR, Chuang LY, Hung WC: Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett. 2001, 508: 365-368. 10.1016/S0014-5793(01)03118-0.CrossRefPubMed Pan MR, Chuang LY, Hung WC: Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett. 2001, 508: 365-368. 10.1016/S0014-5793(01)03118-0.CrossRefPubMed
Metadata
Title
Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression
Authors
Teri L Larkins
Marchele Nowell
Shailesh Singh
Gary L Sanford
Publication date
01-12-2006
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2006
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-6-181

Other articles of this Issue 1/2006

BMC Cancer 1/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine